Evaluation of the role of serum DcR3 levels in the early clinical prognosis of patients with Crimean-Congo hemorrhagic fever

Kerget, Ferhan; Kerget, Buğra; Laloğlu, Esra

doi:10.1016/j.clinbiochem.2023.04.005

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with severe CCHF were more likely to have symptoms including fever, bleeding, nausea, headache, diarrhea, and hypoxia than those with mild/moderate CCHF. In CCHF, which has limited therapeutic choices, elevated DcR3 seen early in the illness may enable the testing of new immunomodulatory treatments in addition to antiviral medication [ 55 ].…”

Section: Crimean–congo Hemorrhagic Fever Virus Life Cyclementioning

confidence: 99%

“…In contrast to other infectious diseases, CCHF can manifest a severe clinical course during the peak season in our endemic region, irrespective of age and comorbidities. Early detection of elevated DcR3 may permit the trial of additional immunomodulatory therapies in CCHF, a condition with limited treatment options beyond antiviral therapy [ 55 ].…”

Section: Advanced Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Muzammil,

Rayyani,

Abbas Sahib

et al. 2024

Biol Proced Online

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus, and zoonosis, and affects large regions of Asia, Southwestern and Southeastern Europe, and Africa. CCHFV can produce symptoms, including no specific clinical symptoms, mild to severe clinical symptoms, or deadly infections. Virus isolation attempts, antigen-capture enzyme-linked immunosorbent assay (ELISA), and reverse transcription polymerase chain reaction (RT-PCR) are all possible diagnostic tests for CCHFV. Furthermore, an efficient, quick, and cheap technology, including biosensors, must be designed and developed to detect CCHFV. The goal of this article is to offer an overview of modern laboratory tests available as well as other innovative detection methods such as biosensors for CCHFV, as well as the benefits and limits of the assays. Furthermore, confirmed cases of CCHF are managed with symptomatic assistance and general supportive care. This study examined the various treatment modalities, as well as their respective limitations and developments, including immunotherapy and antivirals. Recent biotechnology advancements and the availability of suitable animal models have accelerated the development of CCHF vaccines by a substantial margin. We examined a range of potential vaccines for CCHF in this research, comprising nucleic acid, viral particles, inactivated, and multi-epitope vaccines, as well as the present obstacles and developments in this field. Thus, the purpose of this review is to present a comprehensive summary of the endeavors dedicated to advancing various diagnostic, therapeutic, and preventive strategies for CCHF infection in anticipation of forthcoming hazards. Graphical Abstract

show abstract

Section: Crimean–congo Hemorrhagic Fever Virus Life Cyclementioning

confidence: 99%

Section: Advanced Detectionmentioning

confidence: 99%

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Muzammil,

Rayyani,

Abbas Sahib

et al. 2024

Biol Proced Online

View full text Add to dashboard Cite

show abstract

“…DcR3 can competitively bind FasL (TNF superfamily receptor 6, TNFSF6), LIGHT (tumor necrosis factor ligand superfamily member 14, TNFSF14), and TL1A (TNF-like molecule 1A) with a strong affinity through decoy action and can block downstream signaling. Furthermore, it can regulate macrophage and lymphocyte differentiation through non-decoy action and is a multipotent immunomodulator [ 2 , 3 ]. Sepsis is a critical condition characterized by the malfunctioning of organs due to the dysregulation of a patient’s immune response and is triggered by infection.…”

Section: Introductionmentioning

confidence: 99%

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Su,

Tong,

et al. 2023

IJMS

View full text Add to dashboard Cite

Decoy receptor 3 (DcR3), a soluble glycosylated protein in the tumor necrosis factor receptor superfamily, plays a role in tumor and inflammatory diseases. Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the response to infection. Currently, no specific drug that can alleviate or even cure sepsis in a comprehensive and multi-level manner has been found. DcR3 is closely related to sepsis and considerably upregulated in the serum of those patients, and its upregulation is positively correlated with the severity of sepsis and can be a potential biomarker for diagnosis. DcR3 alone or in combination with other markers has shown promising results in the early diagnosis of sepsis. Furthermore, DcR3 is a multipotent immunomodulator that can bind FasL, LIGHT, and TL1A through decoy action, and block downstream apoptosis and inflammatory signaling. It also regulates T-cell and macrophage differentiation and modulates immune status through non-decoy action; therefore, DcR3 could be a potential drug for the treatment of sepsis. The application of DcR3 in the treatment of a mouse model of sepsis also achieved good efficacy. Here, we introduce and discuss the progress in, and suggest novel ideas for, research regarding DcR3 in the diagnosis and treatment of sepsis.

show abstract

Protective effects of DcR3-SUMO on lipopolysaccharide-induced inflammatory cells and septic mice

Su,

Tong,

Feng

et al. 2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Evaluation of the role of serum DcR3 levels in the early clinical prognosis of patients with Crimean-Congo hemorrhagic fever

Cited by 3 publications

References 21 publications

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Protective effects of DcR3-SUMO on lipopolysaccharide-induced inflammatory cells and septic mice

Contact Info

Product

Resources

About